| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1113160233 |
| P356 | DOI | 10.1186/S40169-019-0226-9 |
| P932 | PMC publication ID | 6441665 |
| P698 | PubMed publication ID | 30931508 |
| P2093 | author name string | K M Sullivan | |
| V G Pillarisetty | |||
| K P Labadie | |||
| S K Daniel | |||
| P2860 | cites work | Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin | Q24301757 |
| Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1 | Q24336199 | ||
| Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer | Q24616197 | ||
| B cell regulation of the anti-tumor response and role in carcinogenesis | Q26738867 | ||
| Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer | Q26747806 | ||
| From bench to bedside a comprehensive review of pancreatic cancer immunotherapy | Q26765123 | ||
| The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms | Q26765247 | ||
| Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies | Q26799714 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful | Q27010682 | ||
| HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression | Q27025886 | ||
| Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation | Q27349546 | ||
| The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy | Q28067724 | ||
| The application of the fibroblast activation protein α-targeted immunotherapy strategy | Q28073437 | ||
| Targeting tumor-associated macrophages to combat pancreatic cancer | Q28076103 | ||
| Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1 | Q28081367 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Modulation of macrophage differentiation and activation by decoy receptor 3 | Q28189457 | ||
| PD-L1 Expression in Pancreatic Cancer. | Q53790730 | ||
| Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions. | Q54348110 | ||
| Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. | Q54974100 | ||
| Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. | Q55044320 | ||
| Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis. | Q55265947 | ||
| Targeting adenosine for cancer immunotherapy. | Q55330380 | ||
| The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. | Q55381295 | ||
| Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. | Q55400356 | ||
| Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. | Q55515412 | ||
| Reactive Oxygen Species Regulate Activation-Induced T Cell Apoptosis | Q56922123 | ||
| Harnessing the Induction of CD8 T-Cell Responses Through Metabolic Regulation by Pathogen-Recognition-Receptor Triggering in Antigen Presenting Cells | Q58556287 | ||
| The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy | Q59415963 | ||
| Naïve CD8 T-Cells Engage a Versatile Metabolic Program Upon Activation in Humans and Differ Energetically From Memory CD8 T-Cells | Q60938521 | ||
| Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer | Q62658802 | ||
| Autophagy, p53, and Pancreatic Cancer | Q63865755 | ||
| Pancreatic tumors show high levels of hypoxia | Q73173983 | ||
| CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma | Q75225386 | ||
| Inhibitory effect of tumor cell-derived lactic acid on human T cells | Q79666516 | ||
| Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity | Q80160460 | ||
| Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response | Q80582229 | ||
| The role of circulating dendritic cells in patients with unresectable pancreatic cancer | Q82645727 | ||
| Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection | Q83078978 | ||
| αL β2 integrin is indispensable for CD8+ T-cell recruitment in experimental pancreatic and hepatocellular cancer | Q84290925 | ||
| Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells | Q84623806 | ||
| Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells | Q87780269 | ||
| Hypoxia-inducible factor 1α plays a predominantly negative role in regulatory T cell functions | Q89102378 | ||
| Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy | Q90650277 | ||
| Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes | Q91091017 | ||
| Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions | Q94028943 | ||
| Of mice and not men: differences between mouse and human immunology | Q28246229 | ||
| Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer | Q28259929 | ||
| Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis | Q28344462 | ||
| Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions | Q28476694 | ||
| Targeting hypoxia in cancer therapy | Q29615491 | ||
| FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells | Q31018027 | ||
| Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis | Q33214443 | ||
| Decrease in circulating plasmacytoid dendritic cells during short-term systemic normobaric hypoxia | Q33464094 | ||
| Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. | Q33557006 | ||
| Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment | Q33560501 | ||
| Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells | Q33567728 | ||
| PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation | Q33569771 | ||
| Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine | Q33584867 | ||
| Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia | Q33798508 | ||
| Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. | Q33829094 | ||
| Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells | Q33890964 | ||
| Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo | Q33927370 | ||
| Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor Progression | Q34168497 | ||
| HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment | Q34243443 | ||
| Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells | Q34253642 | ||
| Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer | Q34303116 | ||
| Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer | Q34338082 | ||
| The cellular and molecular origin of tumor-associated macrophages | Q34378833 | ||
| Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer | Q34387974 | ||
| Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis | Q34399827 | ||
| Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango. | Q34438014 | ||
| Organoid models of human and mouse ductal pancreatic cancer | Q34456438 | ||
| CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy | Q34621578 | ||
| Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma | Q34623264 | ||
| Tumor hypoxia enhances Non-Small Cell Lung Cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling | Q34654565 | ||
| Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study. | Q34658445 | ||
| Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells | Q34693614 | ||
| The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? | Q34768306 | ||
| Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction | Q34873308 | ||
| Prognostic value of PDL1 expression in pancreatic cancer | Q37687595 | ||
| Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. | Q37688914 | ||
| Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. | Q37697031 | ||
| Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models | Q37706198 | ||
| CD20+ B cells: the other tumor-infiltrating lymphocytes | Q37801779 | ||
| Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia | Q38064142 | ||
| Role of hypoxia inducible factor-1α for interferon synthesis in mouse dendritic cells | Q38077750 | ||
| Pancreatic stellate cells--multi-functional cells in the pancreas | Q38096605 | ||
| Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. | Q38100593 | ||
| Exploiting the bad eating habits of Ras-driven cancers | Q38151668 | ||
| Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways | Q38176140 | ||
| Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. | Q38219893 | ||
| Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis | Q38238365 | ||
| Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. | Q38239376 | ||
| Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies | Q38262465 | ||
| Addressing the challenges of pancreatic cancer: future directions for improving outcomes | Q38303051 | ||
| Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma | Q38393470 | ||
| The role of pancreatic stellate cells in pancreatic cancer | Q38529484 | ||
| Pancreatic stellate cells: A dynamic player of the intercellular communication in pancreatic cancer | Q38550317 | ||
| CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer | Q38601221 | ||
| TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner | Q38632049 | ||
| Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts | Q38672169 | ||
| Gemcitabine resistance in pancreatic ductal adenocarcinoma | Q38675301 | ||
| Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells | Q38694197 | ||
| Immunotherapy for pancreatic cancer | Q38722325 | ||
| Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway | Q38743164 | ||
| Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. | Q38768285 | ||
| Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer | Q38770259 | ||
| Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis | Q38797313 | ||
| Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. | Q38808099 | ||
| Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer | Q38848404 | ||
| Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma | Q38849286 | ||
| Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses | Q38910729 | ||
| Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. | Q38949999 | ||
| Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner | Q37203714 | ||
| A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma | Q37206372 | ||
| The role of HIF prolyl hydroxylases in tumour growth. | Q37295254 | ||
| Twist promotes angiogenesis in pancreatic cancer by targeting miR-497/VEGFA axis | Q37295501 | ||
| Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells | Q37308216 | ||
| The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth | Q37353804 | ||
| Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism | Q37378754 | ||
| Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer | Q37588378 | ||
| Pancreatic stellate cell: Pandora's box for pancreatic disease biology | Q37624480 | ||
| Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis | Q37628930 | ||
| Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy | Q45871848 | ||
| Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. | Q46373208 | ||
| Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer | Q46453398 | ||
| Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide | Q46535754 | ||
| IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia | Q47098673 | ||
| Cancer statistics, 2018. | Q47191906 | ||
| Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome | Q47769995 | ||
| Influence of hypoxia-inducible factor 1α on dendritic cell differentiation and migration | Q47844444 | ||
| CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer | Q49485242 | ||
| Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer | Q49544289 | ||
| Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells | Q50057466 | ||
| The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression | Q50198413 | ||
| Tumor associated macrophages in gynecologic cancers | Q50209202 | ||
| Short-term hypoxia enhances the migratory capability of dendritic cell through HIF-1α and PI3K/Akt pathway. | Q50663332 | ||
| Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. | Q51731142 | ||
| Periostin Limits Tumor Response to VEGFA Inhibition. | Q52669225 | ||
| CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. | Q52763511 | ||
| Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. | Q52929695 | ||
| Hypoxia affects dendritic cell survival: role of the hypoxia-inducible factor-1α and lipopolysaccharide. | Q53257878 | ||
| Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer | Q34937443 | ||
| A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma | Q34938155 | ||
| Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. | Q35121535 | ||
| CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients | Q35588533 | ||
| L-arginine availability regulates T-lymphocyte cell-cycle progression | Q35628850 | ||
| StellaTUM: current consensus and discussion on pancreatic stellate cell research | Q35633517 | ||
| Importance of culturing primary lymphocytes at physiological oxygen levels | Q35721556 | ||
| Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer | Q35741542 | ||
| Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance | Q35776154 | ||
| Mechanisms and functional significance of tumour-induced dendritic-cell defects | Q35968465 | ||
| A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer | Q36000183 | ||
| Increased expression of surface CD44 in hypoxia-DCs skews helper T cells toward a Th2 polarization | Q36012532 | ||
| Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine | Q36156256 | ||
| Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy | Q36220497 | ||
| Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer | Q36260673 | ||
| HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer | Q36309539 | ||
| Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa | Q36339991 | ||
| Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation | Q36403539 | ||
| Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4 | Q36413897 | ||
| Hypoxia signalling in cancer and approaches to enforce tumour regression | Q36488739 | ||
| HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer | Q36543040 | ||
| Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. | Q36617328 | ||
| Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer | Q36663615 | ||
| Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. | Q36664869 | ||
| Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. | Q36673245 | ||
| Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. | Q36821138 | ||
| CD39 and CD73 in immunity and inflammation | Q36906658 | ||
| Normalizing the environment recapitulates adult human immune traits in laboratory mice | Q36912671 | ||
| Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. | Q36971755 | ||
| Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner | Q36976060 | ||
| Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity | Q36996588 | ||
| Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. | Q37084096 | ||
| Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer | Q37195134 | ||
| Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials | Q38950724 | ||
| A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma | Q38961784 | ||
| Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia | Q38978138 | ||
| L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression | Q39003009 | ||
| Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin | Q39018300 | ||
| Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells | Q39032241 | ||
| A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells | Q39043650 | ||
| HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression | Q39099627 | ||
| Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase | Q39101616 | ||
| Making Mouse Models That Reflect Human Immune Responses | Q39119729 | ||
| Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer | Q39188755 | ||
| Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 | ||
| MYC and HIF in shaping immune response and immune metabolism | Q39211916 | ||
| Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation | Q39400542 | ||
| Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment | Q39409332 | ||
| Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. | Q39507131 | ||
| The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model | Q39604863 | ||
| Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin | Q39796201 | ||
| Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer | Q39856479 | ||
| Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer | Q39893068 | ||
| Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis | Q40079539 | ||
| Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation | Q40124587 | ||
| Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells | Q40241550 | ||
| Pancreatic cancer: Update on immunotherapies and algenpantucel-L. | Q40261599 | ||
| Hypoxia requires notch signaling to maintain the undifferentiated cell state | Q40356897 | ||
| Upregulation of BNIP3 by 5-aza-2'-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. | Q40412450 | ||
| IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer | Q40503359 | ||
| Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine | Q40568618 | ||
| A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. | Q41202462 | ||
| Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. | Q41330055 | ||
| Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer. | Q41367891 | ||
| Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma | Q41514095 | ||
| The impact of hypoxia on tumor-associated macrophages | Q41678839 | ||
| Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy | Q41694098 | ||
| Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma | Q41768958 | ||
| Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells | Q41866335 | ||
| The pancreatic cancer microenvironment: an immunologic battleground | Q41970901 | ||
| Current progress in immunotherapy for pancreatic cancer | Q42086309 | ||
| PanIN-specific regulation of Wnt signaling by HIF2α during early pancreatic tumorigenesis | Q42119856 | ||
| Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer | Q42289841 | ||
| HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression | Q42335712 | ||
| The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review | Q42600273 | ||
| Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors. | Q42682218 | ||
| HIF-1alpha expression regulates the bactericidal capacity of phagocytes | Q42876119 | ||
| HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia | Q43258538 | ||
| Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions | Q44359280 | ||
| Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function | Q44869825 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| immunotherapy | Q1427096 | ||
| pancreatic adenocarcinoma | Q18556189 | ||
| P304 | page(s) | 10 | |
| P577 | publication date | 2019-04-01 | |
| P1433 | published in | Clinical and translational medicine | Q27724586 |
| P1476 | title | Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma | |
| P478 | volume | 8 |
| Q91639548 | CXCL12 and Its Isoforms: Different Roles in Pancreatic Cancer? |
| Q89713724 | Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression |
| Q90193029 | Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges |
| Q94481939 | Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models |
| Q92504704 | Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches |
| Q92541764 | Ping-Pong-Tumor and Host in Pancreatic Cancer Progression |
| Q95273159 | Polymer nanoparticle-assisted chemotherapy of pancreatic cancer |
| Q90098490 | Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy |
| Q90677037 | The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier |
| Q64278826 | The ionophore antibiotic gramicidin A inhibits pancreatic cancer stem cells associated with CD47 down-regulation |
Search more.